HL-007: Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study

Medicine, Brentuximab vedotin, Salvage therapy, Autologous stem-cell transplantation, Internal medicine, Surgery, Regimen, Transplantation, Clinical endpoint, Context (archaeology), Oncology, Lymphoma, Clinical trial, Chemotherapy, Hodgkin lymphoma